Why Amgen Is Down Nearly 7% Today

What happened

Amgen (NASDAQ: AMGN) shares were trading 6.8% lower late Wednesday following a second-quarter earnings beat that was marred by lowered full-year guidance.

So what

The biopharma outfit turned $6.5 billion worth of sales into per-share earnings of $4.38 for the three-month stretch ending in June, both up from year-ago figures, and both topping consensus estimates. Analysts were only modeling a profit of $4.09 per share and revenue of $6.46 billion.

But the challenges created by the pandemic linger. The company lowered its per-share guidance for 2021 to a range of between $8.84 and $9.90, according to generally accepted accounting principles (GAAP), down from prior guidance of between $9.11 and $10.71 per share, as, according to executive vice president Murdo Gordon, "patient visits and lab test procedure trends continue to improve but remain below pre-COVID-19 levels." Fewer doctor-patient visits crimps sales of Amgen's drugs like migraine treatment Aimovig, psoriasis drug Otezla, and arthritis drug Enbrel.

A lab technician working on a pipette.

Image source: Getty Images.

Now what

The market's response to contracted guidance is understandable, but perhaps unmerited. Amgen shares have already been a subpar performer of late, currently trading where they were as of November 2019, and now back to breakeven for the year. Most of the company's prospective challenges were already baked in.

Given this context -- coupled with the fact that Amgen still boasts one of the better portfolios in the pharmaceutical business -- Wednesday's stumble is arguably more of a buying opportunity than a hint of what the future holds. The current dividend yield of 2.9% is also uncharacteristically high for the industry, bolstering the bullish argument. Buyers just need to be prepared for continued volatility.

10 stocks we like better than Amgen
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and Amgen wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of June 7, 2021

James Brumley has no position in any of the stocks mentioned. The Motley Fool recommends Amgen. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More